{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:18:58Z","timestamp":1775024338333,"version":"3.50.1"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Oxaliplatin-based chemotherapy (OX-CT) has shown promising antitumor activity in advanced well-differentiated neuroendocrine tumors (WD-NETs). However, no meta-analysis has been conducted to explore the factors associated with ORR and PFS of OX-CT, and data are still limited in Chinese cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective cohort study with advanced WD-NETs who received OX-CT. We also conducted a systematic review and performed a meta-analysis to explore factors associated with ORR and PFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 27 patients were included, with 21 receiving OX-CT as first line. Furthermore, 18 were of pancreas origin, and the median Ki-67 was 30%. The ORR and DCR were 29.6% and 81.5%, respectively. The median PFS was 9.3 months (95%CI: 4.6\u201314.0), and OS was not reached. A Ki-67 value &amp;gt;10% predicted higher ORR (36.4% vs. 0.0%, <jats:italic>p<\/jats:italic> = 0.28) and better PFS (10.0 vs. 2.1 months, <jats:italic>p<\/jats:italic> = 0.06). Patients with hepatic tumor burden \u226425% had a similar ORR (33.3% vs. 22.2%, <jats:italic>p<\/jats:italic> = 0.68), but with a trend of longer PFS (10.2 vs. 4.7 months, <jats:italic>p<\/jats:italic> = 0.21) than those &amp;gt;25%. Both ORR and PFS were independent of MGMT status. A total of 962 patients were included in the systemic review. The pooled ORR (28.2%, <jats:italic>p<\/jats:italic> = 0.84) and DCR (82.9%, <jats:italic>p<\/jats:italic> = 0.85) were comparable with this cohort. No difference was observed between GEMOX and FOLFOX\/CAPOX in both ORR (23.9% vs. 29.6%, <jats:italic>p<\/jats:italic> = 0.19) and PFS (10.5 vs. 11.8 months, <jats:italic>p<\/jats:italic> = 0.69). Enhanced ORR was seen in pNETs than epNETs (36.8% vs. 16.7%, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and also in G3 NETs than G1\u20132 NETs (45.5% vs. 24.7%, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). The pooled median PFS and OS were 10.8 months (95%CI: 8.8\u201312.8) and 30.4 months (95%CI: 24.8\u201335.9).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Oxaliplatin-based chemotherapy could be a good option for advanced WD-NETs with high Ki-67 index and pancreatic origin.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1595151","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:13:13Z","timestamp":1747195993000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive factors for efficacy of oxaliplatin-based chemotherapy in advanced well-differentiated neuroendocrine tumors: an observational cohort study and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Jian","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxia","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1054","article-title":"FDA approval summary: belzutifan for von Hippel-Lindau disease-associated tumors","volume":"28","author":"Fallah","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4240\/wjgs.v14.i2.78","article-title":"Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives","volume":"14","author":"Merola","year":"2022","journal-title":"World J Gastrointest Surg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11864-019-0669-7","article-title":"The role of cytotoxic chemotherapy in well-differentiated gastroenteropancreatic and lung neuroendocrine tumors","volume":"20","author":"Cives","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ctrv.2016.01.005","article-title":"Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause","volume":"44","author":"Lamarca","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000457955","article-title":"Chemotherapy for well-differentiated pancreatic neuroendocrine tumours with a Ki-67 index >\/=10%: is there a more effective antitumour regimen? A retrospective multicentre study of the French group of endocrine tumours (GTE)","volume":"106","author":"Roquin","year":"2018","journal-title":"Neuroendocrinology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0227","article-title":"Critical appraisal of MGMT in digestive NET treated with alkylating agents","volume":"27","author":"de Mestier","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"key":"B10","article-title":"Wide molecular analysis of PanNET revealed that only MGMT promoter methylation seemed to correlate with Temozolomide response","volume":"34","author":"Cives M","year":"2023","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v121.19","article-title":"Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice","volume":"121","author":"Dussol","year":"2015","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2019.02.001","article-title":"O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET)","volume":"51","author":"Lemelin","year":"2019","journal-title":"Dig Liver Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02724","article-title":"Oxaliplatin-based versus alkylating agent in neuroendocrine tumors according to the O(6)-methylguanine-DNA methyltransferase status: A randomized phase II study (MGMT-NET)","volume":"43","author":"Walter","year":"2025","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e13227","DOI":"10.1111\/jne.13227","article-title":"FOLFOX-bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors","volume":"35","author":"Lacombe","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13309","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours","volume":"35","author":"Rinke","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13423","article-title":"European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J Neuroendocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13306","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3","volume":"35","author":"Panzuto","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0117","article-title":"MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors","volume":"23","author":"Cros","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.02.052","article-title":"Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors","volume":"6","author":"Arnold","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14977","article-title":"Efficacy of FOLFOX chemotherapy in metastatic enteropancreatic neuroendocrine tumors","volume":"41","author":"Oziel-","year":"2021","journal-title":"Anticancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13611","article-title":"Efficacy of FOLFOX in patients with aggressive pancreatic neuroendocrine tumors after prior capecitabine\/temozolomide","volume":"26","author":"Al-Toubah","year":"2021","journal-title":"Oncologist"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2016.1097","article-title":"Systemic chemotherapy with FOLFOX in metastatic grade 1\/2 neuroendocrine cancer","volume":"6","author":"Faure","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jtho.2019.02.002","article-title":"Characterization, prognosis, and treatment of patients with metastatic lung carcinoid tumors","volume":"14","author":"Robelin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1159\/000444087","article-title":"Oxaliplatin-based chemotherapy in advanced neuroendocrine tumors: clinical outcomes and preliminary correlation with biological factors","volume":"103","author":"Spada","year":"2016","journal-title":"Neuroendocrinology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.lungcan.2016.03.018","article-title":"Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors","volume":"96","author":"Walter","year":"2016","journal-title":"Lung Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.3390\/cancers13081936","article-title":"Multicenter analysis of treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors (NET G3)","volume":"13","author":"Apostolidis","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3390\/diagnostics13091595","article-title":"Targeted genomic profiling and chemotherapy outcomes in grade 3 gastro-entero-pancreatic neuroendocrine tumors (G3 GEP-NET)","volume":"13","author":"Lamberti","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-21-0109","article-title":"Treatment outcomes of advanced digestive well-differentiated grade 3 NETs","volume":"28","author":"de Mestier","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4081\/rt.2013.e35","article-title":"Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors","volume":"5","author":"Ferrarotto","year":"2013","journal-title":"Rare Tumors"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1159\/000518650","article-title":"Oxaliplatin and 5-fluorouracil in advanced well-differentiated digestive neuroendocrine tumors: A multicenter national retrospective study from the French group of endocrine tumors","volume":"112","author":"Girot","year":"2022","journal-title":"Neuroendocrinology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001593","article-title":"Efficacy and toxicity of 5-fluorouracil-oxaliplatin in gastroenteropancreatic neuroendocrine neoplasms","volume":"49","author":"Merola","year":"2020","journal-title":"Pancreas"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000000659","article-title":"Oxaliplatin-fluoropyrimidine chemotherapy plus bevacizumab in advanced neuroendocrine tumors: an analysis of 2 phase II trials","volume":"45","author":"Kunz","year":"2016","journal-title":"Pancreas"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0306-6","article-title":"Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours","volume":"59","author":"Bajetta","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1159\/000524988","article-title":"Streptozotocin, 1982-2022: forty years from the FDA\u2019s approval to treat pancreatic neuroendocrine tumors","volume":"112","author":"Capdevila","year":"2022","journal-title":"Neuroendocrinology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"102899","DOI":"10.1016\/j.ctrv.2025.102899","article-title":"The efficacy of streptozotocin in managing pancreatic neuroendocrine neoplasms - A systematic review","volume":"134","author":"Arrivi","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B37","unstructured":"NCCN Clinical Practice Guidelines in Oncology, Neuroendocrine and Adrenal Tumors, Version 1\n          \n          \n          2025"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.7005","article-title":"Efficacy and toxicity analysis of mFOLFIRINOX in high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Borghesani","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/cancers12010206","article-title":"Outcomes of capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs)","volume":"12","author":"Thomas","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1159\/000403785","article-title":"The role of chemotherapy in well-differentiated gastroenteropancreatic neuroendocrine tumors","volume":"44","author":"Strosberg","year":"2015","journal-title":"Front Horm Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s11154-021-09638-0","article-title":"Chemotherapy in NEN: still has a role","volume":"22","author":"Espinosa-Olarte","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"B42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000365514","article-title":"Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms","volume":"100","author":"Schmitt","year":"2014","journal-title":"Neuroendocrinology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.660","article-title":"O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents","volume":"112","author":"Walter","year":"2015","journal-title":"Br J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-10-0028","article-title":"MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases","volume":"17","author":"Corbo","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0147","article-title":"Analysis of potential response predictors to capecitabine\/temozolomide in metastatic pancreatic neuroendocrine tumors","volume":"23","author":"Cives","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1159\/000511905","article-title":"A consensus-developed morphological re-evaluation of 196 high-grade gastroenteropancreatic neuroendocrine neoplasms and its clinical correlations","volume":"111","author":"Elvebakken","year":"2021","journal-title":"Neuroendocrinology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1159\/000513218","article-title":"Temozolomide alone or combined with capecitabine for the treatment of metastatic neuroendocrine neoplasia: A \u201cReal-world\u201d Data analysis","volume":"111","author":"Bongiovanni","year":"2021","journal-title":"Neuroendocrinology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1159\/000510159","article-title":"A Ki-67 index to predict treatment response to the capecitabine\/temozolomide regimen in neuroendocrine neoplasms: A retrospective multicenter study","volume":"111","author":"Wang","year":"2021","journal-title":"Neuroendocrinology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"100119","DOI":"10.1016\/j.esmoop.2021.100119","article-title":"Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study","volume":"6","author":"Jeong","year":"2021","journal-title":"ESMO Open"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3727\/096504021X16214197880808","article-title":"Evaluation of MGMT gene methylation in neuroendocrine neoplasms","volume":"28","author":"Della Monica","year":"2022","journal-title":"Oncol Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3458","article-title":"Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches","volume":"19","author":"Oberg","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000074522","article-title":"Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors\u2013a retrospective single-center analysis","volume":"68","author":"Kress","year":"2003","journal-title":"Digestion"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5591-7","article-title":"Initial treatment of unresectable neuroendocrine tumor liver metastases with transarterial chemoembolization using streptozotocin: A 20-year experience","volume":"24","author":"Dhir","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00270-016-1478-z","article-title":"Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival","volume":"40","author":"Chen","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1595151\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:13:18Z","timestamp":1747195998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1595151\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":57,"alternative-id":["10.3389\/fendo.2025.1595151"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1595151","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"article-number":"1595151"}}